CARISMA Therapeutics Inc. — Form D/A
CARISMA Therapeutics Inc. of PHILADELPHIA, PA, a company, filed a Form D amendment with the SEC on 2018-04-17. The offering totals $3.9M, of which $3.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-04-17
- Form: D/A
- Accession: 0001708649-18-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.9M
- Amount sold: $3.9M
- Investors: 7
- Date of first sale: 2017-05-31
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-288759
Issuer
- Name: CARISMA Therapeutics Inc.
- CIK: 0001708649
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 3675 MARKET STREET, PHILADELPHIA, PA, 19104
- Phone: 484-899-0326
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Michael Poisel | Director | Haddonfield, NJ |
| Michael Heffernan | Director | St. Louis, MO |
| Briggs Morrison | Director | Cambridge, MA |
| Steven Kelly | Director | Solana Beach, CA |
| Steven Kelly | Executive Officer | Solana Beach, CA |
| Althea Stillman | Director | New York, NY |
| Margarita Chavez | Director | San Francisco, CA |
| Bruce Peacock | Director | Philadelphia, PA |
| Bruce Peacock | Executive Officer | Philadelphia, PA |
| Chidozie Ugwumba | Director | Watertown, MA |
| Jacob Gunterberg | Director | Philadelphia, PA |
| Regina Hodits | Director | Philadelphia, PA |
| Eran Nadav | Director | San Francisco, CA |
| Hy Levitsky | Director | Philadelphia, PA |
| Dora Mitchell | Director | Philadelphia, PA |
Other filings by this issuer (5)
More